The Fridley, Minn.-based medtech giant said that Lennon will take over for Mike Hedges, who is retiring from the position after 19 years with Medtronic, including 10 as CIO.
Prior to joining Medtronic, Lennon served as CIO with Allergan (NYSE: AGN), the company said. He has previously held senior leadership positions with pharmaceutical companies including Watson/Actavis, Novartis (NYSE:NVS) and Schering-Plough.
Lasezkay will succeed Daniel White, who resigned as prez, CEO and as a board member to pursue other opportunities, the Alpharetta, Ga.-based company said.
Prior to joining Clearside, Lasezkay acted as exec VP and GC for novel ophthalmic therapeutics maker Acucela and as prez of Horizon Pharma Group. He has also acted as corporate dev corp VP for Allergan, the company said.
“We believe there is tremendous potential in our proprietary suprachoroidal space injection platform, as evidenced by the acceptance of our new drug application for Xipere for suprachoroidal injection. We want to thank Daniel for his visionary contributions, including licensing the original scientific technology, building our versatile therapeutic platform, leading our IPO and other financings, and hiring an experienced team to bring these important innovative products to market. We are at an important stage in the evolution of our company, so we are pleased to have Dr. George Lasezkayserve as CEO on an interim basis as we conduct a search for our next CEO. George has broad expertise in ophthalmology established during his tenure at Allergan, Inc., where he served on the company’s executive committee. With proven management experience and substantial industry knowledge, we believe George will help lead our team as we prepare for commercialization of our first product and look to leverage our unique platform through pipeline expansion and partnerships. We expect to benefit from his combination of clinical, legal, business development and executive expertise, and his diverse experience working with a number of emerging biopharmaceutical companies,” board chair William Humphries said in a press release.
Clearside Biomedical said that it is initiating a search for a permanent replacement.
“We are excited about our suprachoroidal drug delivery platform and potential approval of our first agent for the treatment of macular edema associated with uveitis, which would be a significant milestone for Clearside. We also believe the platform has broad applicability in other eye diseases and continue to explore utilizing suprachoroidal administration with other small molecules and gene therapy. I am confident in the capabilities of the Clearside team and look forward to working with them to ensure the long-term success of Xipere, prudently build our ophthalmic pipeline, and work with potential partners to leverage our platform and provide international reach,” Lasezkay said in a prepared statement.
SynCardia Systems said last week that it promoted current chief operating officer Don Webber to CEO, and that it tapped Peter Spadaro as its new prez & CCO.
Prior to joining Syncardia last year as COO, Webber served as COO at OptiScan and held a manufacturing operations VP position with C.R. Bard, an operations VP position with Ekos and as prez & CEO of Mitralign, Tuscon, Ariz.-based SynCardia said.
Before taking the position with SynCardia, Spadaro held a position as cardiac surgery senior sales director at Medtronic, after having spent nearly 30 years with St. Jude Medical, the company said in a press release.
iHear Medical said last week that it named founder & board chair Adnan Shennib as its new CEO.
The San Leandro, Calif.-based company said that Shennib had spent more than 30 years of experience in founding and leading hearing tech companies, including ReSound and InSound Medical.
iHear Medical also said that Varun Bhardwaj joined the company as operations VP, having previously held the position of chief innovation officer.
Surgical device maker LumeNXT said last week that it named co-founder Paul Rhyne as its new CEO.
Prior to co-founding Boston-based LumeNXT, Rhyne spent time with Intarcia Therapeutics, the company said. Rhyne also spent 11 years at Coloplast Corp., holding positions including Canadian country manager.
“We are proud to name Paul as CEO here at LumeNXT. His wealth of experience and insight into the interaction between the commercial business sector and healthcare space is valuable during this growth stage in our company,” board chair Marc Beer said in a press release.